Developer docs
API playgroundTry for free, no card

Search company profiles

SINOGENE

Full company profile

uuid000339e

Namestring
SINOGENE
Legal namestring
北京希诺谷生物科技有限公司
Websiteurl
sinogene.com.cn
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Sinogene (北京希诺谷生物科技有限公司, Beijing Sinogene Biotechnology Co., Ltd.) is a privately held Chinese animal biotechnology company founded in 2012 in Beijing's Zhongguancun Science Park, operating a proprietary somatic cell cloning and CRISPR/Cas9 gene editing platform. Its core commercial activities span companion animal cloning (dogs and cats), long-term somatic cell cryopreservation at -196°C in liquid nitrogen, pet genetic testing covering 230+ canine and 28+ feline hereditary disease mutations, gene-edited large animal disease models for biomedical research, and equine and pigeon genetic testing. The company was the first in China to commercially clone a dog (Longlong, 2017), the first in China to clone a cat (Garlic, 2019), produced China's first cloned police dog (Kunxun, 2019) and the world's first cloned Arctic wolf (2022), and holds the only commercially operating canine and feline somatic cell cloning capability in the country.

The business model combines high-ticket one-time service revenue from cloning (108,000-380,000 RMB per case, with group-buy promotions as low as 118,000 RMB) and premium genetic testing with recurring subscription-style revenue from multi-year cell preservation plans (9,999-19,000 RMB for 10-year terms), plus B2G contracts for elite working dog cloning with police bureaus and B2B revenue from pharmaceutical and academic customers for gene-edited disease models and preclinical CRO services. Go-to-market is hybrid: a network of 600+ designated partner pet hospitals across China serves as the primary consumer touchpoint and sample collection channel, supplemented by a direct sales hotline, Taobao e-commerce storefront, pet industry exhibitions, and Clone Open Day lab tours in Beijing. Government and academic clients are reached through dedicated B2B/B2G sales, with operational subsidiaries now in Beijing, Jiangsu (Xinyi, opened July 2022, 17,000+ sqm), and Henan (Zhengzhou, opened May 2023), supporting an addressable market spanning individual companion-animal owners, public security agencies, pharmaceutical researchers, and the equine industry.

As of 2023 Sinogene had cloned over 500 animals and built a 100+ employee organization across three operating subsidiaries, with cumulative disclosed funding exceeding US$20 million across rounds led by Renbao Qidi Fund, CCB International's predecessors, and 2024's Series 3 led by CCB International. The company explicitly positions itself as a pet life-cycle management platform whose competitive position rests on proprietary cloning know-how, deep wet-lab talent (including a recognized Zhongguancun postdoctoral station), capital-intensive lab infrastructure, and institutional relationships with the Ministry of Public Security and leading Chinese academic institutions.

Short descriptiontext

Sinogene is a Beijing-headquartered animal biotechnology company that operates China's first commercial somatic cell cloning and CRISPR/Cas9 gene-editing platform, serving individual pet owners, police and military working dog programs, and pharmaceutical / academic research clients with pet cloning, cell preservation, genetic testing, and gene-edited disease models.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChangping, China
HQ citystring
Changping
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pet cloning services, somatic cell cloning, gene editing services, pet genetic testing, animal cell preservation
Industry1 code
PRIMARYAFAEAJAL
Cloning & Advanced Reproductive Technologies Services
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Agricultural Prod-Livestock & Animal Specialties200
Product category
Animal Cloning & Biotechnology Services
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Pet Cloning Services
TypeOne Time License
Description

Core commercial service — cloning of pet dogs and cats using somatic cell nuclear transfer technology. Customers pay upfront fees (38万 RMB for dogs at 2018 pricing) and receive a cloned pet after approximately 10-month process. Includes DNA identity verification by third-party (Nanchang Police Dog Base). Premium pricing with group purchase discounts available periodically.

sinogene.com.cn
2Pet Genetic Testing
TypeOne Time License
Description

DNA-based testing services covering breed composition, hereditary disease screening (230+ canine and 28+ feline mutations), drug sensitivity, parentage testing, and health risk assessment. Sampling done by customers at home using buccal swabs or blood samples. Reports delivered within 2 weeks. Lower price point (starting from 199 RMB for basic tests).

sinogene.com.cn
3Pet Cell/Somatic Cell Preservation
TypeSubscription Recurring
Description

Cryopreservation of pet cells in liquid nitrogen at -196°C for future cloning use. Storage terms available: 1, 3, 5, or 10 years. Pricing tiers: 9,999 RMB for 10-year storage for young healthy pets (promotional price). Customers receive a cell preservation certificate.

sinogene.com.cn
4Working Dog Cloning and Gene Editing Services
TypeOne Time License
Description

B2B service for police, military, and security agencies to clone elite working dogs (search and rescue, drug detection, guide dogs) and create gene-edited disease model dogs for pharmaceutical research. Revenue from government and research institution contracts.

sinogene.com.cn
5Horse Gene Testing and Cloning
TypeOne Time License
Description

Services for equestrian industry including genetic disease testing (22 equine hereditary diseases), speed gene testing, parentage testing, and horse cloning. Partnership with China Horse Association.

sinogene.com.cn
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details8 tiers
1Dog Cloning - Standard Pricing
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Dog cloning: 380,000 RMB (2018 standard price). By 2021 Open Day event: 178,000 RMB for dogs (full payment). Group purchase price in 2021: 118,000 RMB for medium/large dogs (full payment, limited to 50 spots). Pricing includes a 40-day B-scan ultrasound report, birth notification, weekly photo/video updates during the cloning period, and third-party DNA verification from Nanchang Police Dog Base.

sinogene.com.cn
2Dog Cloning - Early Commercial Pricing
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Dog cloning: 380,000 RMB per case (2018-2019 commercial pricing). Deposit payment plans available allowing customers to pay in installments. Customer case cited: 130,000 RMB personal savings + 250,000 RMB borrowed from parents at 6,000 RMB/month mortgage repayment.

sinogene.com.cn
3Cat Cloning - Group Purchase
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Cat cloning group buy: 108,000 RMB (payment in March/April 2021), 118,000 RMB (payment in May 2021). Market price: 250,000 RMB. This was the lowest group price offered. Price is for cloning service only, not including preservation fees. Full payment and contract signing required; deposit option: 138,000 RMB.

sinogene.com.cn
4Cat Cloning - Open Day Promotional Price
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Cat cloning at June 2021 Clone Open Day event: 148,000 RMB. Dog cloning: 178,000 RMB (full payment minimum). Additional benefits: reimbursement of two persons' round-trip airfare/high-speed rail or hard sleeper fares (economy class only), plus one Apple iPhone as gift.

sinogene.com.cn
5Pet Cell Preservation - 10-year Term
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Cell preservation: 19,000 RMB per 10 years (standard price). Promotional price (Jan-Feb 2021 for pets ≤3 years old): 9,999 RMB per 10 years. Original price was 19,000 RMB/10 years before promotion. Includes certificate and annual sample quality testing.

sinogene.com.cn
6Pet Gene Testing - Basic Tier
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Basic gene test: starting from 199 RMB. Full gene testing products offered at discount during Double Eleven (Nov 11) promotions: 20% off for orders exceeding 200 RMB (stackable: 400 RMB gets 40 RMB off, etc.). MDR1 gene test and genetic disease tests available as individual items.

sinogene.com.cn
7Large/Medium Dog Cloning - Group Purchase
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Large and medium dog cloning: market price 300,000-450,000 RMB. Group purchase (2021 year-end promotion, limited to 50 spots): full payment 118,000 RMB; deposit payment 168,000 RMB. Medium dog: 300,000-450,000 RMB standard.

sinogene.com.cn
8Horse Gene Testing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Horse speed gene test: 435 EUR (~3,184 RMB) per test. Racing GenePak product combining speed gene test and distance plus test. Price provided by partner Plusvital; Sinogene offers equivalent services in China with broader content.

sinogene.com.cn
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

SINOGENE provides commercial pet cloning services for dogs and cats using somatic cell nuclear transfer technology, long-term cryopreservation of pet somatic cells in liquid nitrogen at -196°C for future cloning use, and comprehensive pet genetic testing covering breed identification, hereditary disease screening, and drug sensitivity. The company also develops gene-edited large animal disease models (including atherosclerosis and autism model dogs) for pharmaceutical research and working dog cloning services for police and security agencies. SINOGENE built a proprietary animal gene editing and somatic cell cloning technology platform, making it China's first company with fully self-developed commercial pet cloning technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99.9%+ genetic identity between cloned animal and donor confirmed by third-party DNA testing (Nanchang Police Dog Base)
+3 more records
Product overview1 text field

SINOGENE operates as a comprehensive animal gene technology platform offering a full lifecycle management service for pet genetic material. The core offerings include pet cloning (dog and cat), cell preservation, and genetic testing services, supported by proprietary gene editing and somatic cell cloning technology platforms. The company has achieved multiple world firsts in animal cloning including the first gene-edited cloned dog (Longlong, 2017), China's first cloned cat (Garlic, 2019), and the world's first cloned Arctic wolf (2022). Pricing for commercial services includes pet cloning at 38万元 for dogs and starting from 10.8万元 for cats, with cell preservation plans starting at 9,999元 for 10 years.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Beijing Wildlife Park (北京野生动物园)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-19
Description

Co-hosted the world-first cloned Arctic wolf press conference on September 19, 2022. Signifies collaboration between biotech company and wildlife conservation institution for species diversity protection through cloning technology.

sinogene.com.cn
2China Working Dog Management Association (中国工作犬管理协会)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-24
Description

Admitted as group member unit in March 2019. Association operates under Ministry of Public Security. Sinogene aims to collaborate on police dog cloning, working dog cell bank establishment, and breeding research with police dog bases.

sinogene.com.cn
3Chongbai Kingdom (宠爱王国)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-08-23
Description

Signed strategic cooperation agreement August 23, 2019. Jointly established the China Pet Gene Bank. Sinogene brings gene technology; Chongbai Kingdom brings pet big data and digital management systems. Aims to provide full life-cycle management services for pets combining digital and biotech approaches.

sinogene.com.cn
4CKU China Kennel Union (中爱联合犬业俱乐部)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-08-01
Description

FCI's official member in China. Provides authoritative purebred dog management and pedigree standards to support Sinogene's pet gene bank and breeding optimization services.

sinogene.com.cn
5Beijing Municipal Public Security Bureau - Police Dog Base
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-08-01
Description

Police-enterprise collaboration. First collaboration used somatic cell cloning technology to cultivate elite police dogs. Six cloned police dogs born August 2019 formally joined Beijing police force. Project part of 'Precision Breeding Core Technology Research Plan for Police Dogs.'

sinogene.com.cn
6Shanghai Pet Industry Association / Pet Hospital Leaders
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-06-19
Description

Shanghai Pet Industry Association delegation visited Sinogene in June 2019 and signed brand promotion strategic agreements with hospital leaders including Yang Qiqing (president), Tang Feng, Wang Lu, and others. Aimed to expand pet cloning and gene testing market in Shanghai region.

sinogene.com.cn
7Kunming Police Dog Base (公安部昆明警犬基地)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-01
Description

公安部重点研究计划 project 'Gene-edited Working Dog New Variety Breeding.' Kunming Police Dog Base provides elite功勋犬 'Hua Huangma' for cloning. Kunming dogs are China's only domestically developed working dog breed with independent intellectual property.

sinogene.com.cn
8Yunnan Agricultural University (云南农业大学)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-09-01
Description

Co-researcher in the公安部重点研究计划 for gene-edited police dog breeding, alongside Kunming Police Dog Base and Sinogene.

sinogene.com.cn
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Strategic cooperation established September 2019 with Beijing Brain Institute (affiliated with Capital University of Medical Sciences). Jointly established 'Large Animal Model and Drug Evaluation Center.' Focus on cardiovascular and cerebrovascular disease research using gene-edited cloned dogs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Academic collaboration for talent development and research. Dr. Ma Jinlei, a PhD graduate from CAU, initiated the police dog precision breeding project. CAU students conduct internships at Sinogene labs.

11China Horse Association / China Stud Book Committee
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Jointly established 'China Horse Association Equine Genetic Testing and Research Laboratory.' Sinogene Gene (Sinogene subsidiary) provides horse gene testing, parentage testing, speed gene testing, and cloning. China Horse Association provides institutional support and CSBS membership.

sinogene.com.cn
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Established 'Joint Canine Research Laboratory' with the Institute. Provides scientific foundation and research capabilities for gene-edited dog disease models and brain science research initiatives.

13600+ Partner Pet Hospitals
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-01-01
Description

Over 600 high-end pet hospitals across China serve as Sinogene Pet Cloning Designated Hospitals. They distribute genetic testing, cell preservation, and cloning sampling services. Hospitals benefit from adding innovative biotech services to their portfolios.

sinogene.com.cn
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global preclinical CRO specializing in oncology and immuno-oncology animal models and drug discovery services. Comparable to Sinogene's biomedical CRO ambitions but at much larger scale. Acquired by JSR Corporation in 2018. Provides benchmark for scaling preclinical CRO services.

TypeBroad incumbent
Description

Global CRO/CDMO giant with significant preclinical animal model and drug development services. Indirectly comparable as Sinogene expands into pharma CRO services through Jiangsu facility - represents the upper bound of where Sinogene could scale if biomedical CRO ambitions succeed.

TypeDirect peer
Description

South Korean company founded in 2006 by Hwang Woo-suk, world's first commercial dog cloning company. Direct competitor to Sinogene in pet cloning services, offering dog and cat cloning to global customers. Sinogene is noted as 'second only to Sooam' to commercialize dog cloning globally.

TypeDirect peer
Description

US/Australia-based pet and animal cloning company (subsidiary of ViaGen). Cloned the first commercially cloned pet dog in the US and offers equine cloning services. Direct competitor in the premium pet cloning market with comparable somatic cell nuclear transfer technology.

5Boyalife
TypeDirect peer
Description

Chinese biotechnology company with significant investment in animal cloning technology, including plans for a commercial cloning facility. Domestic Chinese peer competing in the same cloning market as Sinogene, particularly for cattle and premium livestock applications.

TypeBroad incumbent
Description

Leading provider of gene-edited mouse/rat models and cell line products headquartered in China. Overlaps with Sinogene's biomedical CRO and gene-edited disease model business, though focuses on rodent rather than large animal (canine) models. Publicly listed on STAR Market.

TypeDirect peer
Description

Italian biotechnology company specializing in animal cloning and reproductive technologies, including horse and livestock cloning. Comparable to Sinogene in technical approach (somatic cell nuclear transfer) and multi-species capability. Smaller-scale competitor in the European market.

8Plusvital
TypeOthers
Description

Irish equine genetics company providing speed gene testing, genetic disease screening, and parentage testing for horses. Direct partner of Sinogene (provides Racing GenePak product), serving the same equine industry customer segment with comparable genetic testing services.

9Beijing Wildlife Park
TypeOthers
Description

Strategic partner of Sinogene for the world's first cloned Arctic wolf (2022). Adjacent organization in the endangered species conservation space that provides venue and institutional credibility for Sinogene's conservation cloning initiatives.

10Ripubio / Ringpu Bio
TypeOthers
Description

Chinese veterinary pharmaceutical company and Series B+ investor in Sinogene (October 2021). Strategic partner providing veterinary pharma expertise and potentially opening veterinary distribution channels. Indirectly comparable as both operate in the Chinese animal health ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SINOGENE

Animal Cloning & Biotechnology Servicessinogene.com.cn

Sinogene is a Beijing-headquartered animal biotechnology company that operates China's first commercial somatic cell cloning and CRISPR/Cas9 gene-editing platform, serving individual pet owners, police and military working dog programs, and pharmaceutical / academic research clients with pet cloning, cell preservation, genetic testing, and gene-edited disease models.

What SINOGENE does

Sinogene (北京希诺谷生物科技有限公司, Beijing Sinogene Biotechnology Co., Ltd.) is a privately held Chinese animal biotechnology company founded in 2012 in Beijing's Zhongguancun Science Park, operating a proprietary somatic cell cloning and CRISPR/Cas9 gene editing platform. Its core commercial activities span companion animal cloning (dogs and cats), long-term somatic cell cryopreservation at -196°C in liquid nitrogen, pet genetic testing covering 230+ canine and 28+ feline hereditary disease mutations, gene-edited large animal disease models for biomedical research, and equine and pigeon genetic testing. The company was the first in China to commercially clone a dog (Longlong, 2017), the first in China to clone a cat (Garlic, 2019), produced China's first cloned police dog (Kunxun, 2019) and the world's first cloned Arctic wolf (2022), and holds the only commercially operating canine and feline somatic cell cloning capability in the country.

The business model combines high-ticket one-time service revenue from cloning (108,000-380,000 RMB per case, with group-buy promotions as low as 118,000 RMB) and premium genetic testing with recurring subscription-style revenue from multi-year cell preservation plans (9,999-19,000 RMB for 10-year terms), plus B2G contracts for elite working dog cloning with police bureaus and B2B revenue from pharmaceutical and academic customers for gene-edited disease models and preclinical CRO services. Go-to-market is hybrid: a network of 600+ designated partner pet hospitals across China serves as the primary consumer touchpoint and sample collection channel, supplemented by a direct sales hotline, Taobao e-commerce storefront, pet industry exhibitions, and Clone Open Day lab tours in Beijing. Government and academic clients are reached through dedicated B2B/B2G sales, with operational subsidiaries now in Beijing, Jiangsu (Xinyi, opened July 2022, 17,000+ sqm), and Henan (Zhengzhou, opened May 2023), supporting an addressable market spanning individual companion-animal owners, public security agencies, pharmaceutical researchers, and the equine industry.

As of 2023 Sinogene had cloned over 500 animals and built a 100+ employee organization across three operating subsidiaries, with cumulative disclosed funding exceeding US$20 million across rounds led by Renbao Qidi Fund, CCB International's predecessors, and 2024's Series 3 led by CCB International. The company explicitly positions itself as a pet life-cycle management platform whose competitive position rests on proprietary cloning know-how, deep wet-lab talent (including a recognized Zhongguancun postdoctoral station), capital-intensive lab infrastructure, and institutional relationships with the Ministry of Public Security and leading Chinese academic institutions.

SINOGENE firmographics

Firmographics
Name
SINOGENE
Legal name
北京希诺谷生物科技有限公司
Website
https://sinogene.com.cn
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Sinogene is a Beijing-headquartered animal biotechnology company that operates China's first commercial somatic cell cloning and CRISPR/Cas9 gene-editing platform, serving individual pet owners, police and military working dog programs, and pharmaceutical / academic research clients with pet cloning, cell preservation, genetic testing, and gene-edited disease models.
Ownership category
akta.pro rank

SINOGENE industry classification

Industry
Product category
Animal Cloning & Biotechnology Services
SIC
Services-Commercial Physical & Biological Research (8731), Agricultural Prod-Livestock & Animal Specialties (200)
akta.pro industry
PRIMARYAFAEAJAL
Cloning & Advanced Reproductive Technologies Services

Keywords

  • Pet cloning services
  • Somatic cell cloning
  • Gene editing services
  • Pet genetic testing
  • Animal cell preservation

Where SINOGENE is headquartered

Location

Headquarters

HQ city
Changping
HQ country
China
HQ region
Asia

Offices3 records

Markets served

SINOGENE business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pet Cloning Services: Core commercial service — cloning of pet dogs and cats using somatic cell nuclear transfer technology. Customers pay upfront fees (38万 RMB for dogs at 2018 pricing) and receive a cloned pet after approximately 10-month process. Includes DNA identity verification by third-party (Nanchang Police Dog Base). Premium pricing with group purchase discounts available periodically.
  2. Pet Genetic Testing: DNA-based testing services covering breed composition, hereditary disease screening (230+ canine and 28+ feline mutations), drug sensitivity, parentage testing, and health risk assessment. Sampling done by customers at home using buccal swabs or blood samples. Reports delivered within 2 weeks. Lower price point (starting from 199 RMB for basic tests).
  3. Pet Cell/Somatic Cell Preservation: Cryopreservation of pet cells in liquid nitrogen at -196°C for future cloning use. Storage terms available: 1, 3, 5, or 10 years. Pricing tiers: 9,999 RMB for 10-year storage for young healthy pets (promotional price). Customers receive a cell preservation certificate.
  4. Working Dog Cloning and Gene Editing Services: B2B service for police, military, and security agencies to clone elite working dogs (search and rescue, drug detection, guide dogs) and create gene-edited disease model dogs for pharmaceutical research. Revenue from government and research institution contracts.
  5. Horse Gene Testing and Cloning: Services for equestrian industry including genetic disease testing (22 equine hereditary diseases), speed gene testing, parentage testing, and horse cloning. Partnership with China Horse Association.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseOne time/ perpetual licenseDog Cloning - Standard Pricing
One time/ perpetual licenseOne time/ perpetual licenseDog Cloning - Early Commercial Pricing
One time/ perpetual licenseOne time/ perpetual licenseCat Cloning - Group Purchase
One time/ perpetual licenseOne time/ perpetual licenseCat Cloning - Open Day Promotional Price
SubscriptionMulti-year contractPet Cell Preservation - 10-year Term
Unit PricingPay-as-you-goPet Gene Testing - Basic Tier
One time/ perpetual licenseOne time/ perpetual licenseLarge/Medium Dog Cloning - Group Purchase
Unit PricingPay-as-you-goHorse Gene Testing

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

SINOGENE product offering

Product offering

Core offering

SINOGENE provides commercial pet cloning services for dogs and cats using somatic cell nuclear transfer technology, long-term cryopreservation of pet somatic cells in liquid nitrogen at -196°C for future cloning use, and comprehensive pet genetic testing covering breed identification, hereditary disease screening, and drug sensitivity. The company also develops gene-edited large animal disease models (including atherosclerosis and autism model dogs) for pharmaceutical research and working dog cloning services for police and security agencies. SINOGENE built a proprietary animal gene editing and somatic cell cloning technology platform, making it China's first company with fully self-developed commercial pet cloning technology.

Product overview

SINOGENE operates as a comprehensive animal gene technology platform offering a full lifecycle management service for pet genetic material. The core offerings include pet cloning (dog and cat), cell preservation, and genetic testing services, supported by proprietary gene editing and somatic cell cloning technology platforms. The company has achieved multiple world firsts in animal cloning including the first gene-edited cloned dog (Longlong, 2017), China's first cloned cat (Garlic, 2019), and the world's first cloned Arctic wolf (2022). Pricing for commercial services includes pet cloning at 38万元 for dogs and starting from 10.8万元 for cats, with cell preservation plans starting at 9,999元 for 10 years.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • 99.9%+ genetic identity between cloned animal and donor confirmed by third-party DNA testing (Nanchang Police Dog Base)
  • +3 more outcomes

Companies that use SINOGENE

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles4 records

SINOGENE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SINOGENE partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Beijing Wildlife Park (北京野生动物园)coreStrategic or Co-development Partner · 19 September 2022Co-hosted the world-first cloned Arctic wolf press conference on September 19, 2022. Signifies collaboration between biotech company and wildlife conservation institution for species diversity protection through cloning technology.
  • China Working Dog Management Association (中国工作犬管理协会)coreStrategic or Co-development Partner · 24 September 2019Admitted as group member unit in March 2019. Association operates under Ministry of Public Security. Sinogene aims to collaborate on police dog cloning, working dog cell bank establishment, and breeding research with police dog bases.
  • Chongbai Kingdom (宠爱王国)coreStrategic or Co-development Partner · 23 August 2019Signed strategic cooperation agreement August 23, 2019. Jointly established the China Pet Gene Bank. Sinogene brings gene technology; Chongbai Kingdom brings pet big data and digital management systems. Aims to provide full life-cycle management services for pets combining digital and biotech approaches.
  • CKU China Kennel Union (中爱联合犬业俱乐部)coreStrategic or Co-development Partner · 1 August 2019FCI's official member in China. Provides authoritative purebred dog management and pedigree standards to support Sinogene's pet gene bank and breeding optimization services.
  • Beijing Municipal Public Security Bureau - Police Dog BasecoreStrategic or Co-development Partner · 1 August 2019Police-enterprise collaboration. First collaboration used somatic cell cloning technology to cultivate elite police dogs. Six cloned police dogs born August 2019 formally joined Beijing police force. Project part of 'Precision Breeding Core Technology Research Plan for Police Dogs.'
  • Shanghai Pet Industry Association / Pet Hospital LeadersminorChannel Partner/ Reseller/ Distributor · 19 June 2019Shanghai Pet Industry Association delegation visited Sinogene in June 2019 and signed brand promotion strategic agreements with hospital leaders including Yang Qiqing (president), Tang Feng, Wang Lu, and others. Aimed to expand pet cloning and gene testing market in Shanghai region.
  • Kunming Police Dog Base (公安部昆明警犬基地)coreStrategic or Co-development Partner · 1 September 2018公安部重点研究计划 project 'Gene-edited Working Dog New Variety Breeding.' Kunming Police Dog Base provides elite功勋犬 'Hua Huangma' for cloning. Kunming dogs are China's only domestically developed working dog breed with independent intellectual property.
  • Yunnan Agricultural University (云南农业大学)coreStrategic or Co-development Partner · 1 September 2018Co-researcher in the公安部重点研究计划 for gene-edited police dog breeding, alongside Kunming Police Dog Base and Sinogene.
  • Beijing Brain Institute (北京脑重大疾病研究院)coreStrategic or Co-development Partner · 1 January 2018Strategic cooperation established September 2019 with Beijing Brain Institute (affiliated with Capital University of Medical Sciences). Jointly established 'Large Animal Model and Drug Evaluation Center.' Focus on cardiovascular and cerebrovascular disease research using gene-edited cloned dogs.
  • China Agricultural University (中国农业大学)coreStrategic or Co-development Partner · 1 January 2018Academic collaboration for talent development and research. Dr. Ma Jinlei, a PhD graduate from CAU, initiated the police dog precision breeding project. CAU students conduct internships at Sinogene labs.
  • China Horse Association / China Stud Book CommitteecoreStrategic or Co-development Partner · 1 January 2018Jointly established 'China Horse Association Equine Genetic Testing and Research Laboratory.' Sinogene Gene (Sinogene subsidiary) provides horse gene testing, parentage testing, speed gene testing, and cloning. China Horse Association provides institutional support and CSBS membership.
  • Chinese Academy of Sciences - Institute of Genetics and Developmental Biology (中科院遗传与发育生物学研究所)coreStrategic or Co-development Partner · 1 January 2018Established 'Joint Canine Research Laboratory' with the Institute. Provides scientific foundation and research capabilities for gene-edited dog disease models and brain science research initiatives.
  • 600+ Partner Pet HospitalscoreChannel Partner/ Reseller/ Distributor · 1 January 2017Over 600 high-end pet hospitals across China serve as Sinogene Pet Cloning Designated Hospitals. They distribute genetic testing, cell preservation, and cloning sampling services. Hospitals benefit from adding innovative biotech services to their portfolios.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

SINOGENE competitors and assessment

Company assessment

Broad incumbents

  • Crown Bioscience: Global preclinical CRO specializing in oncology and immuno-oncology animal models and drug discovery services. Comparable to Sinogene's biomedical CRO ambitions but at much larger scale. Acquired by JSR Corporation in 2018. Provides benchmark for scaling preclinical CRO services.
  • WuXi AppTec: Global CRO/CDMO giant with significant preclinical animal model and drug development services. Indirectly comparable as Sinogene expands into pharma CRO services through Jiangsu facility - represents the upper bound of where Sinogene could scale if biomedical CRO ambitions succeed.
  • Cyagen Biosciences: Leading provider of gene-edited mouse/rat models and cell line products headquartered in China. Overlaps with Sinogene's biomedical CRO and gene-edited disease model business, though focuses on rodent rather than large animal (canine) models. Publicly listed on STAR Market.

Direct peers

  • Sooam Biotech: South Korean company founded in 2006 by Hwang Woo-suk, world's first commercial dog cloning company. Direct competitor to Sinogene in pet cloning services, offering dog and cat cloning to global customers. Sinogene is noted as 'second only to Sooam' to commercialize dog cloning globally.
  • Viagen Pets: US/Australia-based pet and animal cloning company (subsidiary of ViaGen). Cloned the first commercially cloned pet dog in the US and offers equine cloning services. Direct competitor in the premium pet cloning market with comparable somatic cell nuclear transfer technology.
  • Boyalife: Chinese biotechnology company with significant investment in animal cloning technology, including plans for a commercial cloning facility. Domestic Chinese peer competing in the same cloning market as Sinogene, particularly for cattle and premium livestock applications.
  • Avantea: Italian biotechnology company specializing in animal cloning and reproductive technologies, including horse and livestock cloning. Comparable to Sinogene in technical approach (somatic cell nuclear transfer) and multi-species capability. Smaller-scale competitor in the European market.

Others

  • Plusvital: Irish equine genetics company providing speed gene testing, genetic disease screening, and parentage testing for horses. Direct partner of Sinogene (provides Racing GenePak product), serving the same equine industry customer segment with comparable genetic testing services.
  • Beijing Wildlife Park: Strategic partner of Sinogene for the world's first cloned Arctic wolf (2022). Adjacent organization in the endangered species conservation space that provides venue and institutional credibility for Sinogene's conservation cloning initiatives.
  • Ripubio / Ringpu Bio: Chinese veterinary pharmaceutical company and Series B+ investor in Sinogene (October 2021). Strategic partner providing veterinary pharma expertise and potentially opening veterinary distribution channels. Indirectly comparable as both operate in the Chinese animal health ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

SINOGENE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SINOGENE leadership team

Management profile

Number of profiles

Profiles9 records

SINOGENE subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

SINOGENE funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SINOGENE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SINOGENE

What does SINOGENE do?

SINOGENE provides commercial pet cloning services for dogs and cats using somatic cell nuclear transfer technology, long-term cryopreservation of pet somatic cells in liquid nitrogen at -196°C for future cloning use, and comprehensive pet genetic testing covering breed identification, hereditary disease screening, and drug sensitivity. The company also develops gene-edited large animal disease models (including atherosclerosis and autism model dogs) for pharmaceutical research and working dog cloning services for police and security agencies. SINOGENE built a proprietary animal gene editing and somatic cell cloning technology platform, making it China's first company with fully self-developed commercial pet cloning technology.

Is SINOGENE a public or private company?

SINOGENE is a private company. It is classified as venture growth investor backed and is currently operating.

When was SINOGENE founded?

SINOGENE was founded in 2012. It employs 11 to 50 people.

Where is SINOGENE based?

SINOGENE is headquartered in Changping, China, in the Asia region.

How does SINOGENE make money?

Five revenue lines are on record. Pet Cloning Services are the primary driver. The others are pet Genetic Testing, pet Cell/Somatic Cell Preservation, working Dog Cloning and Gene Editing Services and horse Gene Testing and Cloning.

Who are SINOGENE's main competitors?

Broad incumbents on record are Crown Bioscience, WuXi AppTec and Cyagen Biosciences. Direct peers are Sooam Biotech, Viagen Pets, Boyalife and Avantea. Others are Plusvital, Beijing Wildlife Park and Ripubio / Ringpu Bio.

Does SINOGENE have an API?

No public API is recorded for SINOGENE.

What industry is SINOGENE in?

SINOGENE's product category is Animal Cloning & Biotechnology Services. Its primary akta.pro industry code is AFAEAJAL, Cloning & Advanced Reproductive Technologies Services. Its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The MirrorBeagle dog gives birth to cloned Arctic wolf in world's 'first case of its kind'A cloned Arctic wolf named Maya was born to a surrogate beagle in a Beijing lab, derived from a skin cell of her genetic mother. The first such cloning was done by Sinogene, with 137 embryos created and only one puppy born. A second cloned wolf is expected in coming weeks.ItvBeagle gives birth to world's first cloned Arctic wolfSinogene cloned an Arctic wolf from a 16-year-old female's skin cell, born to a surrogate Beagle in June. The first cloned Arctic wolf, Maya, is genetically identical to her donor, and the process involved 137 embryos transferred to seven beagles.Miami HeraldWhat does a cloned arctic wolf look like? Watch these adorable pups play in ChinaSinogene Biotechnology released photos and videos of cloned arctic wolf pups born in China. The first pup, Maya, was born June 10 and named after a Harbin Polar Park wolf; a second male, Zhao, was born Sept. 28. Maya has been taken to the Harbin Polar Park.The Jerusalem PostMeet Maya, the world's first cloned arctic wolfSinogene Biotechnology announced the birth of the world's first cloned Arctic wolf, Maya, at a press conference in Beijing. The wolf was born on June 10 and is still in the lab with her surrogate mother. The company aims to use cloning for endangered species conservation.Popular MechanicsThe First Cloned Arctic Wolf Has Been Born Via a Beagle in ChinaSinogene Biotechnology announced on September 19 that a cloned Arctic wolf named Maya was born on June 10 to a beagle surrogate in a Beijing lab. The company used donor cells from a wild female Arctic wolf to create 137 embryos, with only one healthy pup born. A second cloned pup was expected on September 22.PeoplemagBeagle Surrogate Mom Gives Birth to World's First Cloned Arctic Wolf, Researchers RevealSinogene Biotechnology cloned an Arctic wolf named Maya, born to a beagle surrogate in June, using somatic cell nuclear transfer. The company announced the healthy pup in September, and she will eventually be moved to Harbin Polarland, where she may live alone initially.Global TimesSecond cloned arctic wolf born, proving cloning tech to be effective in recovery of endangered speciesThe second cloned arctic wolf, Ha'er, was born on September 22 in a Sinogene Biotechnology lab in Xuzhou, China. The cub weighed 571 grams and was 20 centimeters long, with donor cells from a wild male arctic wolf. Researchers plan to breed Ha'er and Maya and apply cloning to other endangered species.Tech TimesChinese Scientists Clone an Arctic Wolf With Beagle as Surrogate MotherSinogene Biotechnology announced the birth of the world's first cloned Arctic wolf, Maya, carried by a beagle surrogate. The company used somatic cell nuclear transfer on DNA from a deceased wolf, producing 137 embryos implanted into seven beagles, with one developing to term. A second clone is due to give birth on Sept. 22.ScienceAlertThe World's First Cloned Wolf Has Reportedly Been Born in China, And It's AdorableSinogene Biotechnology announced the birth of the world's first cloned Arctic wolf, Maya, in Beijing, carried by a beagle surrogate. The company also said a second clone was due on Sept. 22. Sinogene plans to use cloning for endangered species conservation.SYFY Official SiteA beagle gave birth to the world’s first arctic wolf cloneSinogene Biotechnology cloned an arctic wolf named Maya, the world's first, using a beagle surrogate. Of 137 embryos, only one succeeded, and Maya is healthy. The company plans to collaborate with Beijing Wildlife Park for genetic preservation of endangered species.